Cell replacement therapies hold tremendous promise for type 1 diabetes, hemophilia, lysosomal storage diseases and other cellular disorders. EncapBio Systems has developed technologies for safe and functional delivery of cell therapies ready for pre-clinical development. Most of our recent work, ranging from material synthesis and device fabrication to cell engineering and process integration, has been centered around the goal of successfully delivering safely insulin producing cells with long-term function for T1D patients. EncapBio Systems builds upon 10 years of research of high quality proof-of-concept publications and patent applications. EncapBio Systems is seeking co-founders and investors to help build the next biomaterial platform for cell therapy.
The FloraPulse system is a microchip tensiometer (microtensiometer) that is embedded into the tree woody tissue and directly measures the water status, known as water potential. Because the measurement is taken directly inside the water-carrying tissue, readings are very accurate and reliable. You receive daily midday stem water potential readings, along with science-backed irrigation recommendations. Since 2017, we raised $1.2M in non-dilutive SBIR research awards to develop microT, and successfully field tested the product in almond, grape and prune commercial orchards and vineyards. In 2019-2020, we received $50k in customer deposits and sold the first 60 subscriptions ($90k) to 15 customers in the US, Chile and Australia. Customer feedback has been very positive. We are looking to hire a seasoned CEO to help the company raise funds, build partnerships, and continue increasing product sales in the US and abroad.
Current clinical diagnostic methods require confirmation by invasive procedures such as a biopsy of the gut, skin, or liver, while protein marker tests are limited to few tissue types and do not detect infections. Short fragments of cell-free DNA circulate in blood, urine and other biofluids and offer an information-rich window into human physiology, with rapidly expanding applications in prenatal testing, cancer screening, organ transplant monitoring and infectious disease testing. Our research pursues technologies and applications of cell-free DNA in infectious and immune-related disease.
Stork.ai is leveraging its strong foundations in reproductive medicine, big data, and artificial intelligence to create next-generation fertility products that ultimately help people have babies. It is commercializing a decision assessment tool comprised of patent-pending, AI-based software (“STORK”) that reliably assesses embryo (blastocyst) quality. STORK was developed using a proprietary, multi-focal embryo image dataset from Weill Cornell’s Center for Reproductive Medicine. STORK can also predict genetic defects such as aneuploidy, which involves an abnormal number of chromosomes in the embryo.
This device allows for damage free handling of sensitive devices and surfaces, and for applications that involve quick attach and release of surfaces. The total market opportunity for this company is approximately 36 billion. Conventional techniques to grab surfaces use a vacuum/suction strategy but these suffer an intrinsic limit of adhesion strength—1 atm (approximately 100 kPa) and are bulky. The switchable adhesion device is an electro-osmotic pump that uses individually-controlled oscillating water droplets to easily, carefully and quickly pick and place tiles in parallel.
Key nutrient deficiencies are more common than one may think and can lead to major health problems. However, determining vitamin levels can be costly, time-consuming, and confusing. VitaScan enables fast, accurate, and low-cost testing of an individual's vitamins and micronutrients. With VitaScan's portable system, the consumer can avoid hospital blood work and get the scan done at a physician's office, clinic, or even at home.
About half of treated cancer patients receive platinum-based drugs (eg. cisplatin, carboplatin) alone or in co-administration with other anticancer agents. Despite their efficacy, their use is limited by toxic side effects and inherent or acquired resistance to platinum-based drugs by tumor cells. To address this challenge, a Cornell team lead by Prof. Justin Wilson have developed rhenium-based chemotherapeutics for treatment of platinum-resistant cancers.
90% of cancer-related deaths occur due to metastasis. While effective therapies exist to treat primary tumors, treatments to slow/stop metastasis remain ineffective. While immuno-oncology is a new avenue for fighting these metastasized tumors, priming the immune cells has proven difficult. Here, the lab of Prof. King demonstrates a new method to functionalize immune cells. This technology can be applied to metastatic forms of prostate (1.1 million men diagnosed in 2012) and colorectal cancer (1.2 million cases diagnosed in 2015.)
Solutions for silent speech production lack innovation, cultural acceptability, and often involve invasive surgery. MyophonX is cutting-edge wearable technology for silent communication, with applications to stroke and laryngectomy patients as well as voice searching.
Exotanium is a startup created by two professors and one graduated Ph.D. student from the Department of Computer Science at Cornell University. Exotanium is developing a new cloud-native application container platform that improves performance, security, and cost for both public and private clouds. The technology is based on cutting-edge research and is patent-protected. Exotanium recently won a Small Business Innovation Research (SBIR) award from the National Science Foundation (NSF) and is actively raising more investments. The company is located in Ithaca, NY.